Skip to main content
Top
Published in: Angiogenesis 3/2014

01-07-2014 | Original Paper

Breast tumor cell TACE-shed MCSF promotes pro-angiogenic macrophages through NF-κB signaling

Authors: Stephen L. Rego, Rachel S. Helms, Didier Dréau

Published in: Angiogenesis | Issue 3/2014

Login to get access

Abstract

Most deaths associated with breast cancer, the most common malignancy in women, are caused by metastasis. Tumor associated macrophages significantly contribute to breast cancer progression and development of metastasis through the promotion of angiogenesis which involves a central regulator of macrophage functions: nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Macrophages are activated by macrophage colony stimulating factor (MCSF) and chemokine (C–C motif) ligand 2 (CCL2) to secrete angiogenic factors including vascular endothelial growth factor (VEGF). The release of MCSF from tumor cells is mediated by ectodomain shedding through tumor necrosis factor alpha converting enzyme activation (TACE). Here we determined whether tumor cells TACE-shed MCSF promotes angiogenesis through activation of the NF-κB pathway in macrophages and the subsequent release of VEGF. These interactions were modeled in vitro using a panel of mammary cells mimicking the breast cancer progression from normal murine mammary gland cells to metastatic 4T1 cells along with J774 macrophages, all derived from BALB/c mice. TACE and MCSF expressions were higher in metastatic cells compared to epithelial cells (p < 0.05). Tumor conditioned medias activated the expression of VEGF by macrophages through stimulation of the NF-κB pathway and resulting macrophage secretions that promoted high levels of endothelial cell tubes. Furthermore, the combinations of CCL2, also highly expressed by tumor cells, and MCSF promoted pro-angiogenic macrophages. These results highlight the key role of tumor cell TACE-shed MCSF and secreted CCL2 in stimulating pro-angiogenic macrophages.
Literature
2.
go back to reference American Cancer Society (2013) Cancer Facts and Figures 2013. American Cancer Society, Atlanta American Cancer Society (2013) Cancer Facts and Figures 2013. American Cancer Society, Atlanta
4.
go back to reference Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer progression. Novartis Found Symp 256:158–168 discussion 168–172, 259–169PubMedCrossRef Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer progression. Novartis Found Symp 256:158–168 discussion 168–172, 259–169PubMedCrossRef
5.
go back to reference Kelly PM, Davison RS, Bliss E, McGee JO (1988) Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer 57(2):174–177PubMedCentralPubMedCrossRef Kelly PM, Davison RS, Bliss E, McGee JO (1988) Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer 57(2):174–177PubMedCentralPubMedCrossRef
9.
go back to reference Arribas J, Esselens C (2009) ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 15(20):2319–2335PubMedCrossRef Arribas J, Esselens C (2009) ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des 15(20):2319–2335PubMedCrossRef
11.
go back to reference Horiuchi K, Miyamoto T, Takaishi H, Hakozaki A, Kosaki N, Miyauchi Y, Furukawa M, Takito J, Kaneko H, Matsuzaki K, Morioka H, Blobel CP, Toyama Y (2007) Cell surface colony-stimulating factor 1 can be cleaved by TNF-α converting enzyme or endocytosed in a clathrin-dependent manner. J Immunol 179(10):6715–6724PubMedCrossRef Horiuchi K, Miyamoto T, Takaishi H, Hakozaki A, Kosaki N, Miyauchi Y, Furukawa M, Takito J, Kaneko H, Matsuzaki K, Morioka H, Blobel CP, Toyama Y (2007) Cell surface colony-stimulating factor 1 can be cleaved by TNF-α converting enzyme or endocytosed in a clathrin-dependent manner. J Immunol 179(10):6715–6724PubMedCrossRef
12.
go back to reference Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385(6618):729–733. doi:10.1038/385729a0 PubMedCrossRef Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385(6618):729–733. doi:10.​1038/​385729a0 PubMedCrossRef
13.
go back to reference Lee DC, Sunnarborg SW, Hinkle CL, Myers TJ, Stevenson MY, Russell WE, Castner BJ, Gerhart MJ, Paxton RJ, Black RA, Chang A, Jackson LF (2003) TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann N Y Acad Sci 995:22–38PubMedCrossRef Lee DC, Sunnarborg SW, Hinkle CL, Myers TJ, Stevenson MY, Russell WE, Castner BJ, Gerhart MJ, Paxton RJ, Black RA, Chang A, Jackson LF (2003) TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann N Y Acad Sci 995:22–38PubMedCrossRef
14.
go back to reference Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D’Souza SE (2006) Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 281(6):3157–3164. doi:10.1074/jbc.M510797200 PubMedCrossRef Tsakadze NL, Sithu SD, Sen U, English WR, Murphy G, D’Souza SE (2006) Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 281(6):3157–3164. doi:10.​1074/​jbc.​M510797200 PubMedCrossRef
18.
go back to reference Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555PubMedCrossRef Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11):549–555PubMedCrossRef
19.
go back to reference Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL (2004) Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10(1 Pt 1):173–177PubMedCrossRef Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL (2004) Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10(1 Pt 1):173–177PubMedCrossRef
20.
go back to reference Scholl SM, Lidereau R, de la Rochefordiere A, Le-Nir CC, Mosseri V, Nogues C, Pouillart P, Stanley FR (1996) Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Res Treat 39(3):275–283PubMedCrossRef Scholl SM, Lidereau R, de la Rochefordiere A, Le-Nir CC, Mosseri V, Nogues C, Pouillart P, Stanley FR (1996) Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Res Treat 39(3):275–283PubMedCrossRef
21.
25.
go back to reference Weigand M, Hantel P, Kreienberg R, Waltenberger J (2005) Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8(3):197–204. doi:10.1007/s10456-005-9010-0 PubMedCrossRef Weigand M, Hantel P, Kreienberg R, Waltenberger J (2005) Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8(3):197–204. doi:10.​1007/​s10456-005-9010-0 PubMedCrossRef
26.
go back to reference Rugo HS (2004) Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9(Suppl 1):43–49PubMedCrossRef Rugo HS (2004) Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9(Suppl 1):43–49PubMedCrossRef
28.
go back to reference Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32):4286–4293. doi:10.1200/JCO.2010.34.1255 PubMedCrossRef Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O’Neill V, Rugo HS (2011) RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 29(32):4286–4293. doi:10.​1200/​JCO.​2010.​34.​1255 PubMedCrossRef
29.
go back to reference Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E (2003) VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase-defective form of the IκB kinase 2. J Cell Sci 116(Pt 4):665–674PubMedCrossRef Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E (2003) VEGF expression in human macrophages is NF-κB-dependent: studies using adenoviruses expressing the endogenous NF-κB inhibitor IκBα and a kinase-defective form of the IκB kinase 2. J Cell Sci 116(Pt 4):665–674PubMedCrossRef
32.
go back to reference Wang G, Chen C, Yang R, Cao X, Lai S, Luo X, Feng Y, Xia X, Gong J, Hu J (2013) p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-κB pathway. Angiogenesis. doi:10.1007/s10456-013-9336-y Wang G, Chen C, Yang R, Cao X, Lai S, Luo X, Feng Y, Xia X, Gong J, Hu J (2013) p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF-κB pathway. Angiogenesis. doi:10.​1007/​s10456-013-9336-y
34.
go back to reference Maxson S, Burg KJ (2008) Conditioned media cause increases in select osteogenic and adipogenic differentiation markers in mesenchymal stem cell cultures. J Tissue Eng Regen Med 2(2–3):147–154. doi:10.1002/term.76 PubMedCrossRef Maxson S, Burg KJ (2008) Conditioned media cause increases in select osteogenic and adipogenic differentiation markers in mesenchymal stem cell cultures. J Tissue Eng Regen Med 2(2–3):147–154. doi:10.​1002/​term.​76 PubMedCrossRef
35.
37.
go back to reference Rego SL, Swamydas M, Kidiyoor A, Helms R, De Piante A, Lance AL, Mukherjee P, Dreau D (2013) Soluble tumor necrosis factor receptors shed by breast tumor cells inhibit macrophage chemotaxis. J Interferon Cytokine Res. doi:10.1089/jir.2013.0009 PubMed Rego SL, Swamydas M, Kidiyoor A, Helms R, De Piante A, Lance AL, Mukherjee P, Dreau D (2013) Soluble tumor necrosis factor receptors shed by breast tumor cells inhibit macrophage chemotaxis. J Interferon Cytokine Res. doi:10.​1089/​jir.​2013.​0009 PubMed
41.
go back to reference Lance A, Yang CC, Swamydas M, Dean D, Deitch S, Burg KJ, Dreau D (2013) Increased extracellular matrix density decreases MCF10A breast cell acinus formation in 3D culture conditions. J Tissue Eng Regen Med. doi:10.1002/term.1675 PubMed Lance A, Yang CC, Swamydas M, Dean D, Deitch S, Burg KJ, Dreau D (2013) Increased extracellular matrix density decreases MCF10A breast cell acinus formation in 3D culture conditions. J Tissue Eng Regen Med. doi:10.​1002/​term.​1675 PubMed
43.
46.
go back to reference Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561–566PubMedCrossRef Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2(5):561–566PubMedCrossRef
48.
go back to reference Trad A, Riese M, Shomali M, Hedeman N, Effenberger T, Grotzinger J, Lorenzen I (2013) The disintegrin domain of ADAM17 antagonises fibroblastcarcinoma cell interactions. Int J Oncol 42(5):1793–1800. doi:10.3892/ijo 2013.1864PubMed Trad A, Riese M, Shomali M, Hedeman N, Effenberger T, Grotzinger J, Lorenzen I (2013) The disintegrin domain of ADAM17 antagonises fibroblastcarcinoma cell interactions. Int J Oncol 42(5):1793–1800. doi:10.​3892/​ijo 2013.1864PubMed
49.
52.
go back to reference Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB (2003) M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 171(5):2637–2643PubMedCrossRef Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB (2003) M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 171(5):2637–2643PubMedCrossRef
57.
go back to reference Salcedo R, Resau JH, Halverson D, Hudson EA, Dambach M, Powell D, Wasserman K, Oppenheim JJ (2000) Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 14(13):2055–2064. doi:10.1096/fj.99-0963com PubMedCrossRef Salcedo R, Resau JH, Halverson D, Hudson EA, Dambach M, Powell D, Wasserman K, Oppenheim JJ (2000) Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells. FASEB J 14(13):2055–2064. doi:10.​1096/​fj.​99-0963com PubMedCrossRef
58.
go back to reference Varney ML, Olsen KJ, Mosley RL, Singh RK (2005) Paracrine regulation of vascular endothelial growth factor—a expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. J Interferon Cytokine Res 25(11):674–683. doi:10.1089/jir.2005.25.674 PubMedCrossRef Varney ML, Olsen KJ, Mosley RL, Singh RK (2005) Paracrine regulation of vascular endothelial growth factor—a expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. J Interferon Cytokine Res 25(11):674–683. doi:10.​1089/​jir.​2005.​25.​674 PubMedCrossRef
59.
go back to reference Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O’Day SJ (2012) BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30(1):34–41. doi:10.1200/JCO.2011.34.6270 PubMedCrossRef Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE 3rd, O’Day SJ (2012) BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30(1):34–41. doi:10.​1200/​JCO.​2011.​34.​6270 PubMedCrossRef
60.
go back to reference Rego SL, Helms RS, Dréau D (2013) Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer. Immunol Res. doi: 10.1007/s12026-013-8434-7 Rego SL, Helms RS, Dréau D (2013) Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer. Immunol Res. doi: 10.​1007/​s12026-013-8434-7
Metadata
Title
Breast tumor cell TACE-shed MCSF promotes pro-angiogenic macrophages through NF-κB signaling
Authors
Stephen L. Rego
Rachel S. Helms
Didier Dréau
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 3/2014
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-013-9405-2

Other articles of this Issue 3/2014

Angiogenesis 3/2014 Go to the issue